A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors

Charity Knight, Vera Logan, Deborah Fenlon, Charity Knight, Vera Logan, Deborah Fenlon

Abstract

Women who have been treated for breast cancer may experience vulvo-vaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM). This is a progressive condition and will not improve without treatment. Whilst vaginal oestrogen is the most effective treatment for GSM, many breast cancer survivors and clinicians remain reluctant to use it. Laser therapy is emerging as an alternative treatment for this condition but there is little evidence available as to its value in this setting. We undertook a systematic literature review to identify available evidence for the use of laser therapy for VVA in women with breast cancer. There are a number of small studies which suggest an improvement in vaginal health in this group. However, these are all small, non-randomised studies and there are a number of key questions which need to be answered before this treatment can be implemented into practice.

Keywords: atrophic vaginitis; breast neoplasms; cancer survivors; laser therapy.

Conflict of interest statement

No authors have any competing conflicts of interest.

© the authors; licensee ecancermedicalscience.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6974376/bin/can-13-988fig1.jpg

References

    1. Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. Lasers Med Sci. 2018;33(5):1047–1054. doi: 10.1007/s10103-018-2471-3.
    1. Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the study of women’s sexual health. Menopause. 2018;25(6):596–608. doi: 10.1097/GME.0000000000001121.
    1. Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. Maturitas. 2017;99:10–15. doi: 10.1016/j.maturitas.2017.01.012.
    1. Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24(3):316–319. doi: 10.1097/GME.0000000000000761.
    1. Gaspar A, Addamo G, Brandi H. Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation. Am J Cosmetic Surg. 2011;28(3):156–162. doi: 10.1177/074880681102800309.
    1. Janik J, Markus J, Al-Dujaili L, et al. Laser resurfacing. Semin Plast Surg. 2007;21(3):139–146. doi: 10.1055/s-2007-991182.
    1. Jones GL, Sutton A. Quality of life in obese postmenopausal women. Menopause Int. 2008;14(1):26–32. doi: 10.1258/mi.2007.007034.
    1. Kerr JB. Atlas of Functional Histology. London: Mosby; 2000. pp. 39–40. and 337.
    1. Kingsberg S, Krychman M, Graham S, et al. The women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14:413–424. doi: 10.1016/j.jsxm.2017.01.010.
    1. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;31(8):CD001500.
    1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clinic Proceedings. 2010;85(1):87–94. doi: 10.4065/mcp.2009.0413.
    1. Mandal D, Nunns D, Byrne M, et al. Guidelines for the management of vulvodynia. Br J Dermatol. 2010;162(6):1180–1185. doi: 10.1111/j.1365-2133.2010.09684.x.
    1. Mothes AR, Runnebaum M, Runnebaum IB. Ablative dual-phase erbium: YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. J Cancer Res Clin Oncol. 2018;144(5):955–960. doi: 10.1007/s00432-018-2614-8.
    1. Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views and attitudes (VIVA) – results from an international survey. Climacteric. 2012;15(1):36–44. doi: 10.3109/13697137.2011.647840.
    1. Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233–238. doi: 10.1016/j.maturitas.2010.08.001.
    1. NICE Guideline (CG123) Urinary incontinence and pelvic organ prolapse in women: management. 2019.
    1. NICE Guideline (NG23) Menopause: diagnosis and management. 2015.
    1. NICE Pathway. Managing menopausal symptoms. 2018.
    1. Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause. 2018;25(6):657–662. doi: 10.1097/GME.0000000000001053.
    1. Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437–47. doi: 10.2147/IJWH.S44579.
    1. Perrotta C, Aznar M, Mejia R, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;16(2):CD005131.
    1. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294(4):841–846. doi: 10.1007/s00404-016-4118-6.
    1. Ponzone R, Biglia N, Jacomuzzi ME, et al. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer. 2005;41(17):2673–2681. doi: 10.1016/j.ejca.2005.07.015.
    1. Salvatore S, Nappi RE, Zerbinati N, et al. A 12 week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363–369. doi: 10.3109/13697137.2014.899347.
    1. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6:2133–2142. doi: 10.1111/j.1743-6109.2009.01335.x.
    1. Sokol E, Karram M. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. Menopause. 2017;24(7):810–814. doi: 10.1097/GME.0000000000000839.
    1. Trinkaus M, Chin S, Wolfman W, et al. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist. 2008;13(3):222–231. doi: 10.1634/theoncologist.2007-0234.
    1. Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015;30:429–436. doi: 10.1007/s10103-014-1677-2.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner